Pharma & Biotech

Organogenesis Holdings Inc. finds itself at a fascinating crossroads this week, caught between strong institutional confidence and a challenging quarterly...

Alx Oncology Holdings finds itself navigating contrasting currents as significant clinical advancements coincide with disappointing quarterly financial performance. The biopharma...

The coming days present two pivotal events for Anixa Biosciences that are likely to dictate the near-term trajectory of its...

Sysmex Corporation has announced the acquisition of JEOL's clinical chemistry testing business, which includes the BioMajesty product line. The company's...

Bayer's pharmaceutical division has encountered a significant clinical development hurdle as its promising heart failure drug candidate, Vericiguat, failed to...

In the intensifying battle for dominance in the multi-billion dollar weight-loss drug market, Novo Nordisk has delivered a powerful counterpunch....

Iovance Biotherapeutics finds itself at a critical juncture as it prepares for significant investor conferences in early September. These events...

Pharmaceutical giant Eli Lilly, already reaping billions from its revolutionary weight-loss and diabetes treatments, may be on the verge of...

Cardiff Oncology enters a crucial period with three major investor conferences scheduled for early September, providing the biotechnology firm with...

Sarepta Therapeutics finds itself at a pivotal crossroads as it transitions from the S&P MidCap 400 to the S&P SmallCap...